PD-1 immunotherapy, chemotherapy, and radiation for advanced cervical cancer
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests whether chemotherapy plus an immune treatment called PD-1, along with radiation, can help people with cervical cancer that cannot be removed with surgery. It’s aimed at locally advanced, unresectable cervical squamous cell cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Have been diagnosed by pathology with cervical squamous cell carcinoma
- Your cervical cancer is considered unresectable (cannot be removed with surgery)
- You must not have any active autoimmune disease right now
- You must not have had certain autoimmune problems in the past that are still ongoing or currently active
- Examples of excluded autoimmune conditions include lung inflammation, eye inflammation (uveitis), bowel inflammation (enteritis), or hepatitis-related illness
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of cadonilimab (an immune-boosting drug) plus chemotherapy for locally advanced cervical cancer that hasn't been treated before. The goal is to see if this combination helps shrink tumors and improve outcomes before surgery.
This trial tests whether combining chemotherapy with immunotherapy before surgery can help treat cervical cancer that is PD-L1 negative. It's for women with larger tumors (stage IB3 to IIB) who have not been treated yet.
This study tests whether adding immunotherapy to chemotherapy, then giving chemotherapy together with radiation, works better for advanced cervical cancer. It aims to improve cancer control and help people live longer, without major safety issues.
This trial tests whether a combination of chemotherapy and immunotherapy (pembrolizumab) before surgery works better than standard chemoradiation for locally advanced cervical cancer. It may help shrink tumors more effectively.
This trial tests if giving chemotherapy plus an immunotherapy drug before surgery can help shrink tumors and improve outcomes for patients with stage IB2 cervical cancer that has not been treated yet. It might be an option if you have a specific type of cervical cancer that shows a certain protein (PD-L1) on your tumor cells.
This trial tests a combination of chemotherapy (nab-paclitaxel plus cisplatin) given together with radiation therapy for people with locally advanced cervical cancer. The goal is to see if this treatment is safe and effective.
Hear when a new Neoadjuvant Chemotherapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.